Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEXANDER N STARODUB

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1124087135
CMS profile
6028
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$14,561.76

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $14,561.76 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEXANDER N STARODUB

NPI 1124087135 · CMS profile ID 6028

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124087135?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEXANDER N STARODUB, NPI 1124087135, CMS profile ID 6028. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124087135?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ALEXANDER N STARODUB, NPI 1124087135, CMS profile ID 6028. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124087135?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ALEXANDER N STARODUB, NPI 1124087135, CMS profile ID 6028, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124087135?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $14,561.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $2,520.0009/15/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891851 CMS
E.R. Squibb & Sons, L.L.C. $2,520.0008/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891857 CMS
E.R. Squibb & Sons, L.L.C. $2,535.0006/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891845 CMS
E.R. Squibb & Sons, L.L.C. $500.0006/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891883 CMS
E.R. Squibb & Sons, L.L.C. $1,000.0005/26/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891878 CMS
E.R. Squibb & Sons, L.L.C. $360.7003/26/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891841 CMS
E.R. Squibb & Sons, L.L.C. $5,070.0002/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891831 CMS
E.R. Squibb & Sons, L.L.C. $6.2502/11/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891819 CMS
E.R. Squibb & Sons, L.L.C. $49.8102/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891825 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40,702.59 55
PY2020 $14,561.76 9
PY2021 $6,470.00 4
PY2022 $3,527.70 20
PY2023 $6,052.49 26
PY2024 $239.67 4
PY2025 $71.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $181,361.55 30
PY2024 Principal investigator $286,229.93 39
PY2023 Principal investigator $372,024.13 41
PY2022 Principal investigator $106.50 1
PY2021 Principal investigator $13,750.00 5
PY2020 Principal investigator $11,421.34 16
PY2019 Principal investigator $156,760.95 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Exelixis Inc. $3,328.60 12/20/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632206
Principal investigator 1 Ascendis Pharma Inc $7,900.00 12/16/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
TCTLR-101 No dispute reported 06/30/2026 1133845309
Principal investigator 1 Ascendis Pharma Inc $9,978.80 12/16/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845620
Principal investigator 1 Ascendis Pharma Inc $14,853.02 12/06/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845608
Principal investigator 1 AstraZeneca UK Limited $10,698.00 12/05/2024 Non-covered Recipient Entity
THE CARL AND EDYTH LINDNER CENTER FOR RESEARCH AND EDUCATION
an observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD No dispute reported 06/30/2026 1110845395
Principal investigator 1 Ascendis Pharma Inc $215.80 11/19/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845603
Principal investigator 1 Mirati Therapeutics, Inc. $4,432.80 11/19/2024 Covered Recipient Teaching Hospital
The Christ Hospital
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1124762944
Principal investigator 1 Exelixis Inc. $24,955.15 11/15/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632196
Principal investigator 1 Ascendis Pharma Inc $821.10 11/11/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845592
Principal investigator 1 BioNTech SE $97.00 11/01/2024 Covered Recipient Teaching Hospital
The Christ Hospital
BNT327-01 No dispute reported 06/30/2026 1150667547
Principal investigator 1 BioNTech SE $97.00 11/01/2024 Covered Recipient Teaching Hospital
The Christ Hospital
BNT327-01 No dispute reported 06/30/2026 1150667549
Principal investigator 1 Exelixis Inc. $3,348.15 10/28/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632198
Principal investigator 1 Exelixis Inc. $5,850.00 10/16/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632200
Principal investigator 1 Exelixis Inc. $1,690.00 10/16/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632202
Principal investigator 1 Exelixis Inc. $4,680.00 10/16/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632204
Principal investigator 1 Ascendis Pharma Inc $3,637.40 10/04/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845580
Principal investigator 1 Ascendis Pharma Inc $8,427.90 09/17/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845544
Principal investigator 1 Ascendis Pharma Inc $573.30 09/17/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845555
Principal investigator 1 Exelixis Inc. $11,461.40 08/30/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632192
Principal investigator 1 Ascendis Pharma Inc $7,584.20 07/19/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845548
Principal investigator 1 Ascendis Pharma Inc $3,805.10 07/12/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845552
Principal investigator 1 Exelixis Inc. $17,634.10 07/05/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632194
Principal investigator 1 Exelixis Inc. $739.70 06/20/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632190
Principal investigator 1 Exelixis Inc. $4,872.40 05/23/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632186
Principal investigator 1 Exelixis Inc. $1,950.00 05/15/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632184
Principal investigator 1 Exelixis Inc. $7,285.20 05/15/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632188
Principal investigator 1 Exelixis Inc. $739.70 04/24/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632172
Principal investigator 1 Exelixis Inc. $1,690.00 04/24/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632174
Principal investigator 1 Exelixis Inc. $614.90 04/24/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632176
Principal investigator 1 Exelixis Inc. $112.26 04/24/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632178
Principal investigator 1 Exelixis Inc. $971.10 04/24/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632180
Principal investigator 1 Exelixis Inc. $3,367.70 04/19/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632182
Principal investigator 1 Ascendis Pharma Inc $12,700.00 03/27/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
BelieveIT-201 No dispute reported 06/30/2026 1133854759
Principal investigator 1 Ascendis Pharma Inc $2,403.70 03/08/2024 Non-covered Recipient Entity
The Carl and Edyth Lindner Center
IL Believe No dispute reported 06/30/2026 1133845532
Principal investigator 1 Exelixis Inc. $28,485.20 02/21/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632170
Principal investigator 1 Exelixis Inc. $2,774.20 02/15/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632168
Principal investigator 1 PFIZER INC. $1,825.00 02/14/2024 Non-covered Recipient Entity
Carl Edyth Lindner Center for Research Education at The Christ Hospital
A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT No dispute reported 06/30/2026 1131093546
Principal investigator 1 Exelixis Inc. $61,330.05 01/26/2024 Non-covered Recipient Entity
THE CARL & EDYTH LINDNER CENTER FOR RESEARCH & EDUCATION AT THE CHRIST HOSPITAL
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1138632166
Principal investigator 1 PFIZER INC. $8,300.00 01/26/2024 Non-covered Recipient Entity
Carl Edyth Lindner Center for Research Education at The Christ Hospital
A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT No dispute reported 06/30/2026 1131093587